Home » Knowledge Center » PDX-derived organoids (PDXO) are valuable tools to unveil the shortcomings of new anti-cancer drug candidates
PDX-derived organoids (PDXO) are valuable tools to unveil the shortcomings of new anti-cancer drug candidates
Tumor organoids are increasingly being recognized as predictive preclinical cancer models because they reflect original tumor features and patient drug responses. However, systematic comparisons betweenorganoids and traditional 2D cell lines or 3D spheroids are lacking. In this study, we compared the response of PDXO models and traditional tumor cell line models to clinical cancer drugs. Drug efficacy and multi-omics data from the organoid models are the basis for predicting the clinical drug response in this promising in vitro model and identifying potential drug resistance mechanisms.